日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Corticosteroids ameliorate CAR T-cell-induced cytokine-release syndrome without inhibiting multiple myeloma treatment

皮质类固醇可缓解CAR-T细胞诱导的细胞因子释放综合征,且不抑制多发性骨髓瘤的治疗。

Amatya, Christina; Weissler, Katherine A; Lam, Norris; Natrakul, Danielle A; Brudno, Jennifer N; Cutmore, Lauren C; Mikkilineni, Lekha; Kochenderfer, James N

Chimeric antigen receptor T cell therapy for autoimmune disease

嵌合抗原受体T细胞疗法治疗自身免疫性疾病

Chung, James B; Brudno, Jennifer N; Borie, Dominic; Kochenderfer, James N

Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial

改良版FOLFOX6方案联合贝伐珠单抗(加或不加纳武利尤单抗)一线治疗转移性结直肠癌:CheckMate 9X8随机临床试验的II期结果

Lenz, Heinz-Josef; Parikh, Aparna; Spigel, David R; Cohn, Allen L; Yoshino, Takayuki; Kochenderfer, Mark; Elez, Elena; Shao, Spencer H; Deming, Dustin; Holdridge, Regan; Larson, Timothy; Chen, Eric; Mahipal, Amit; Ucar, Antonio; Cullen, Dana; Baskin-Bey, Edwina; Kang, Tong; Hammell, Amy B; Yao, Jin; Tabernero, Josep

Optimization of anti-CD19 CAR T cell production for treatment of patients with chronic lymphocytic leukemia

优化抗 CD19 CAR-T 细胞生产用于治疗慢性淋巴细胞白血病患者

Christina Amatya, Katherine A Weissler, Vicki Fellowes, Norris Lam, Lauren C Cutmore, Danielle A Natrakul, Steven L Highfill, James N Kochenderfer

Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial

Idecabtagene vicleucel 用于复发/难治性多发性骨髓瘤:一项 1 期试验的事后 18 个月随访

Yi Lin ,Noopur S Raje ,Jesús G Berdeja ,David S Siegel ,Sundar Jagannath ,Deepu Madduri ,Michaela Liedtke ,Jacalyn Rosenblatt ,Marcela V Maus ,Monica Massaro ,Fabio Petrocca ,Ashish Yeri ,Olivia Finney ,Andrea Caia ,Zhihong Yang ,Nathan Martin ,Timothy B Campbell ,Julie Rytlewski ,Jaymes Fuller ,Kristen Hege ,Nikhil C Munshi ,James N Kochenderfer

Genome-wide profiling of retroviral DNA integration and its effect on clinical pre-infusion CAR T-cell products

逆转录病毒 DNA 整合的全基因组分析及其对临床输注前 CAR-T 细胞产品的影响

Lipei Shao, Rongye Shi, Yingdong Zhao, Hui Liu, Alexander Lu, Jinxia Ma, Yihua Cai, Tatyana Fuksenko, Alejandra Pelayo, Nirali N Shah, James N Kochenderfer, Scott M Norberg, Christian Hinrichs, Steven L Highfill, Robert P Somerville, Sandhya R Panch, Ping Jin, David F Stroncek

Yearlong COVID-19 Infection Reveals Within-Host Evolution of SARS-CoV-2 in a Patient With B-Cell Depletion

长达一年的 COVID-19 感染揭示了 B 细胞耗竭患者体内 SARS-CoV-2 的宿主内演变

Nussenblatt, Veronique; Roder, Allison E; Das, Sanchita; de Wit, Emmie; Youn, Jung-Ho; Banakis, Stephanie; Mushegian, Alexandra; Mederos, Christopher; Wang, Wei; Chung, Matthew; Pérez-Pérez, Lizzette; Palmore, Tara; Brudno, Jennifer N; Kochenderfer, James N; Ghedin, Elodie

Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma

在B细胞淋巴瘤患者中,具有全人源结合域的抗CD19 CAR T细胞的安全性和可行性

Jennifer N Brudno ,Norris Lam ,Danielle Vanasse ,Yueh-Wei Shen ,Jeremy J Rose ,John Rossi ,Allen Xue ,Adrian Bot ,Nathalie Scholler ,Lekha Mikkilineni ,Mark Roschewski ,Robert Dean ,Raul Cachau ,Philippe Youkharibache ,Rashmika Patel ,Brenna Hansen ,David F Stroncek ,Steven A Rosenberg ,Ronald E Gress ,James N Kochenderfer

Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma

在B细胞淋巴瘤患者中,具有全人源结合域的抗CD19 CAR T细胞的安全性和可行性

Jennifer N Brudno,Norris Lam,Danielle Vanasse,Yueh-Wei Shen,Jeremy J Rose,John Rossi,Allen Xue,Adrian Bot,Nathalie Scholler,Lekha Mikkilineni,Mark Roschewski,Robert Dean,Raul Cachau,Philippe Youkharibache,Rashmika Patel,Brenna Hansen,David F Stroncek,Steven A Rosenberg,Ronald E Gress,James N Kochenderfer

Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains

具有完全人源重链抗原识别结构域的抗BCMA嵌合抗原受体

Norris Lam ,Nathan D Trinklein ,Benjamin Buelow ,George H Patterson ,Namrata Ojha ,James N Kochenderfer